Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 289 to 298 of 298 entries
Sorted by: Best Match Show Resources per page
MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones.

EBioMedicine

Gitto S, Cuocolo R, van Langevelde K, van de Sande MAJ, Parafioriti A, Luzzati A, Imbriaco M, Sconfienza LM, Bloem JL.
PMID: 34933178
EBioMedicine. 2021 Dec 18;75:103757. doi: 10.1016/j.ebiom.2021.103757. Epub 2021 Dec 18.

BACKGROUND: Atypical cartilaginous tumour (ACT) and grade II chondrosarcoma (CS2) of long bones are respectively managed with watchful waiting or curettage and wide resection. Preoperatively, imaging diagnosis can be challenging due to interobserver variability and biopsy suffers from sample...

Cite
Gitto S, Cuocolo R, van Langevelde K, et al. MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones. EBioMedicine. 2021;75:103757doi: 10.1016/j.ebiom.2021.103757.
Gitto, S., Cuocolo, R., van Langevelde, K., van de Sande, M. A. J., Parafioriti, A., Luzzati, A., Imbriaco, M., Sconfienza, L. M., & Bloem, J. L. (2021). MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones. EBioMedicine, 75103757. https://doi.org/10.1016/j.ebiom.2021.103757
Gitto, Salvatore, et al. "MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones." EBioMedicine vol. 75 (2021): 103757. doi: https://doi.org/10.1016/j.ebiom.2021.103757
Gitto S, Cuocolo R, van Langevelde K, van de Sande MAJ, Parafioriti A, Luzzati A, Imbriaco M, Sconfienza LM, Bloem JL. MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones. EBioMedicine. 2021 Dec 18;75:103757. doi: 10.1016/j.ebiom.2021.103757. Epub 2021 Dec 18. PMID: 34933178.
Copy Download .nbib Format: NLM
Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender.

Journal of substance use

Xie S, Minami H, Kumar DS, Hecht J, Bloom EL, Kahler C, Abrantes A, Price LH, Ondersma S, Brown RA.
PMID: 34899051
J Subst Use. 2021;26(6):669-676. doi: 10.1080/14659891.2021.1879295. Epub 2020 Sep 28.

Smoking prevalence among individuals in substance use treatment remains higher than in the general population. Given that many smokers in substance use treatment are reluctant to quit smoking, it is important to understand the factors that impede smokers' readiness...

Cite
Xie S, Minami H, Kumar DS, et al. Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender. J Subst Use. 2020;26(6):669-676doi: 10.1080/14659891.2021.1879295.
Xie, S., Minami, H., Kumar, D. S., Hecht, J., Bloom, E. L., Kahler, C., Abrantes, A., Price, L. H., Ondersma, S., & Brown, R. A. (2021). Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender. Journal of substance use, 26(6), 669-676. https://doi.org/10.1080/14659891.2021.1879295
Xie, Siwen, et al. "Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender." Journal of substance use vol. 26,6 (2021): 669-676. doi: https://doi.org/10.1080/14659891.2021.1879295
Xie S, Minami H, Kumar DS, Hecht J, Bloom EL, Kahler C, Abrantes A, Price LH, Ondersma S, Brown RA. Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender. J Subst Use. 2021;26(6):669-676. doi: 10.1080/14659891.2021.1879295. Epub 2020 Sep 28. PMID: 34899051; PMCID: PMC8659404.
Copy Download .nbib Format: NLM
The genomics of heart failure: design and rationale of the HERMES consortium.

ESC heart failure

Lumbers RT, Shah S, Lin H, Czuba T, Henry A, Swerdlow DI, Mälarstig A, Andersson C, Verweij N, Holmes MV, Ärnlöv J, Svensson P, Hemingway H, Sallah N, Almgren P, Aragam KG, Asselin G, Backman JD, Biggs ML, Bloom HL, Boersma E, Brandimarto J, Brown MR, Brunner-La Rocca HP, Carey DJ, Chaffin MD, Chasman DI, Chazara O, Chen X, Chen X, Chung JH, Chutkow W, Cleland JGF, Cook JP, de Denus S, Dehghan A, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Engström G, Esko T, Fatemifar G, Felix SB, Finan C, Ford I, Fougerousse F, Fouodjio R, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gui H, Gutmann R, Haggerty CM, van der Harst P, Hedman ÅK, Helgadottir A, Hillege H, Hyde CL, Jacob J, Jukema JW, Kamanu F, Kardys I, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Kraus B, Kuchenbaecker K, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Mann D, Margulies KB, Marston NA, März W, McMurray JJV, Melander O, Melloni G, Mordi IR, Morley MP, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP, Newton-Cheh C, Niessner A, Niiranen T, Nowak C, O'Donoghue ML, Owens AT, Palmer CNA, Paré G, Perola M, Perreault LL, Portilla-Fernandez E, Psaty BM, Rice KM, Ridker PM, Romaine SPR, Roselli C, Rotter JI, Ruff CT, Sabatine MS, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, Stefansson K, Stender S, Stott DJ, Sveinbjörnsson G, Tammesoo ML, Tardif JC, Taylor KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tuckwell D, Tyl B, Uitterlinden AG, Vaura F, Veluchamy A, Visscher PM, Völker U, Voors AA, Wang X, Wareham NJ, Weeke PE, Weiss R, White HD, Wiggins KL, Xing H, Yang J, Yang Y, Yerges-Armstrong LM, Yu B, Zannad F, Zhao F, Wilk JB, Holm H, Sattar N, Lubitz SA, Lanfear DE, Shah S, Dunn ME, Wells QS, Asselbergs FW, Hingorani AD, Dubé MP, Samani NJ, Lang CC, Cappola TP, Ellinor PT, Vasan RS, Smith JG.
PMID: 34480422
ESC Heart Fail. 2021 Dec;8(6):5531-5541. doi: 10.1002/ehf2.13517. Epub 2021 Sep 03.

AIMS: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure.METHODS AND RESULTS: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases...

Cite
Lumbers RT, Shah S, Lin H, et al. The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Fail. 2021;8(6):5531-5541doi: 10.1002/ehf2.13517.
Lumbers, R. T., Shah, S., Lin, H., Czuba, T., Henry, A., Swerdlow, D. I., Mälarstig, A., Andersson, C., Verweij, N., Holmes, M. V., Ärnlöv, J., Svensson, P., Hemingway, H., Sallah, N., Almgren, P., Aragam, K. G., Asselin, G., Backman, J. D., Biggs, M. L., Bloom, H. L., Boersma, E., Brandimarto, J., Brown, M. R., Brunner-La Rocca, H. P., Carey, D. J., Chaffin, M. D., Chasman, D. I., Chazara, O., Chen, X., Chen, X., Chung, J. H., Chutkow, W., Cleland, J. G. F., Cook, J. P., de Denus, S., Dehghan, A., Delgado, G. E., Denaxas, S., Doney, A. S., Dörr, M., Dudley, S. C., Engström, G., Esko, T., Fatemifar, G., Felix, S. B., Finan, C., Ford, I., Fougerousse, F., Fouodjio, R., Ghanbari, M., Ghasemi, S., Giedraitis, V., Giulianini, F., Gottdiener, J. S., Gross, S., Guðbjartsson, D. F., Gui, H., Gutmann, R., Haggerty, C. M., van der Harst, P., Hedman, �. �. K., Helgadottir, A., Hillege, H., Hyde, C. L., Jacob, J., Jukema, J. W., Kamanu, F., Kardys, I., Kavousi, M., Khaw, K. T., Kleber, M. E., Køber, L., Koekemoer, A., Kraus, B., Kuchenbaecker, K., Langenberg, C., Lind, L., Lindgren, C. M., London, B., Lotta, L. A., Lovering, R. C., Luan, J., Magnusson, P., Mahajan, A., Mann, D., Margulies, K. B., Marston, N. A., März, W., McMurray, J. J. V., Melander, O., Melloni, G., Mordi, I. R., Morley, M. P., Morris, A. D., Morris, A. P., Morrison, A. C., Nagle, M. W., Nelson, C. P., Newton-Cheh, C., Niessner, A., Niiranen, T., Nowak, C., O'Donoghue, M. L., Owens, A. T., Palmer, C. N. A., Paré, G., Perola, M., Perreault, L. L., Portilla-Fernandez, E., Psaty, B. M., Rice, K. M., Ridker, P. M., Romaine, S. P. R., Roselli, C., Rotter, J. I., Ruff, C. T., Sabatine, M. S., Salo, P., Salomaa, V., van Setten, J., Shalaby, A. A., Smelser, D. T., Smith, N. L., Stefansson, K., Stender, S., Stott, D. J., Sveinbjörnsson, G., Tammesoo, M. L., Tardif, J. C., Taylor, K. D., Teder-Laving, M., Teumer, A., Thorgeirsson, G., Thorsteinsdottir, U., Torp-Pedersen, C., Trompet, S., Tuckwell, D., Tyl, B., Uitterlinden, A. G., Vaura, F., Veluchamy, A., Visscher, P. M., Völker, U., Voors, A. A., Wang, X., Wareham, N. J., Weeke, P. E., Weiss, R., White, H. D., Wiggins, K. L., Xing, H., Yang, J., Yang, Y., Yerges-Armstrong, L. M., Yu, B., Zannad, F., Zhao, F., Wilk, J. B., Holm, H., Sattar, N., Lubitz, S. A., Lanfear, D. E., Shah, S., Dunn, M. E., Wells, Q. S., Asselbergs, F. W., Hingorani, A. D., Dubé, M. P., Samani, N. J., Lang, C. C., Cappola, T. P., Ellinor, P. T., Vasan, R. S., & Smith, J. G. (2021). The genomics of heart failure: design and rationale of the HERMES consortium. ESC heart failure, 8(6), 5531-5541. https://doi.org/10.1002/ehf2.13517
Lumbers, R Thomas, et al. "The genomics of heart failure: design and rationale of the HERMES consortium." ESC heart failure vol. 8,6 (2021): 5531-5541. doi: https://doi.org/10.1002/ehf2.13517
Lumbers RT, Shah S, Lin H, Czuba T, Henry A, Swerdlow DI, Mälarstig A, Andersson C, Verweij N, Holmes MV, Ärnlöv J, Svensson P, Hemingway H, Sallah N, Almgren P, Aragam KG, Asselin G, Backman JD, Biggs ML, Bloom HL, Boersma E, Brandimarto J, Brown MR, Brunner-La Rocca HP, Carey DJ, Chaffin MD, Chasman DI, Chazara O, Chen X, Chen X, Chung JH, Chutkow W, Cleland JGF, Cook JP, de Denus S, Dehghan A, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Engström G, Esko T, Fatemifar G, Felix SB, Finan C, Ford I, Fougerousse F, Fouodjio R, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gui H, Gutmann R, Haggerty CM, van der Harst P, Hedman ÅK, Helgadottir A, Hillege H, Hyde CL, Jacob J, Jukema JW, Kamanu F, Kardys I, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Kraus B, Kuchenbaecker K, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Mann D, Margulies KB, Marston NA, März W, McMurray JJV, Melander O, Melloni G, Mordi IR, Morley MP, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP, Newton-Cheh C, Niessner A, Niiranen T, Nowak C, O'Donoghue ML, Owens AT, Palmer CNA, Paré G, Perola M, Perreault LL, Portilla-Fernandez E, Psaty BM, Rice KM, Ridker PM, Romaine SPR, Roselli C, Rotter JI, Ruff CT, Sabatine MS, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, Stefansson K, Stender S, Stott DJ, Sveinbjörnsson G, Tammesoo ML, Tardif JC, Taylor KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tuckwell D, Tyl B, Uitterlinden AG, Vaura F, Veluchamy A, Visscher PM, Völker U, Voors AA, Wang X, Wareham NJ, Weeke PE, Weiss R, White HD, Wiggins KL, Xing H, Yang J, Yang Y, Yerges-Armstrong LM, Yu B, Zannad F, Zhao F, Wilk JB, Holm H, Sattar N, Lubitz SA, Lanfear DE, Shah S, Dunn ME, Wells QS, Asselbergs FW, Hingorani AD, Dubé MP, Samani NJ, Lang CC, Cappola TP, Ellinor PT, Vasan RS, Smith JG. The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Fail. 2021 Dec;8(6):5531-5541. doi: 10.1002/ehf2.13517. Epub 2021 Sep 03. PMID: 34480422; PMCID: PMC8712846.
Copy Download .nbib Format: NLM
Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach.

NPJ Parkinson's disease

Marques TM, van Rumund A, Kersten I, Bruinsma IB, Wessels HJCT, Gloerich J, Kaffa C, Esselink RAJ, Bloem BR, Kuiperij HB, Verbeek MM.
PMID: 34848724
NPJ Parkinsons Dis. 2021 Nov 30;7(1):107. doi: 10.1038/s41531-021-00249-9.

The aim of our study was to investigate cerebrospinal fluid (CSF) tryptic peptide profiles as potential diagnostic biomarkers for the discrimination of parkinsonian disorders. CSF samples were collected from individuals with parkinsonism, who had an uncertain diagnosis at the...

Cite
Marques TM, van Rumund A, Kersten I, et al. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. NPJ Parkinsons Dis. 2021;7(1):107doi: 10.1038/s41531-021-00249-9.
Marques, T. M., van Rumund, A., Kersten, I., Bruinsma, I. B., Wessels, H. J. C. T., Gloerich, J., Kaffa, C., Esselink, R. A. J., Bloem, B. R., Kuiperij, H. B., & Verbeek, M. M. (2021). Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. NPJ Parkinson's disease, 7(1), 107. https://doi.org/10.1038/s41531-021-00249-9
Marques, Tainá M, et al. "Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach." NPJ Parkinson's disease vol. 7,1 (2021): 107. doi: https://doi.org/10.1038/s41531-021-00249-9
Marques TM, van Rumund A, Kersten I, Bruinsma IB, Wessels HJCT, Gloerich J, Kaffa C, Esselink RAJ, Bloem BR, Kuiperij HB, Verbeek MM. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. NPJ Parkinsons Dis. 2021 Nov 30;7(1):107. doi: 10.1038/s41531-021-00249-9. PMID: 34848724.
Copy Download .nbib Format: NLM
Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender.

Journal of substance use

Xie S, Minami H, Kumar DS, Hecht J, Bloom EL, Kahler C, Abrantes A, Price LH, Ondersma S, Brown RA.
PMID: 34899051
J Subst Use. 2021;26(6):669-676. doi: 10.1080/14659891.2021.1879295. Epub 2020 Sep 28.

Smoking prevalence among individuals in substance use treatment remains higher than in the general population. Given that many smokers in substance use treatment are reluctant to quit smoking, it is important to understand the factors that impede smokers' readiness...

Cite
Xie S, Minami H, Kumar DS, et al. Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender. J Subst Use. 2020;26(6):669-676doi: 10.1080/14659891.2021.1879295.
Xie, S., Minami, H., Kumar, D. S., Hecht, J., Bloom, E. L., Kahler, C., Abrantes, A., Price, L. H., Ondersma, S., & Brown, R. A. (2021). Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender. Journal of substance use, 26(6), 669-676. https://doi.org/10.1080/14659891.2021.1879295
Xie, Siwen, et al. "Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender." Journal of substance use vol. 26,6 (2021): 669-676. doi: https://doi.org/10.1080/14659891.2021.1879295
Xie S, Minami H, Kumar DS, Hecht J, Bloom EL, Kahler C, Abrantes A, Price LH, Ondersma S, Brown RA. Readiness to Quit Smoking among Smokers in Substance Use Treatment: Associations with Stress, Substance Use Severity, Relapse Concerns and Gender. J Subst Use. 2021;26(6):669-676. doi: 10.1080/14659891.2021.1879295. Epub 2020 Sep 28. PMID: 34899051; PMCID: PMC8659404.
Copy Download .nbib Format: NLM
Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Kroesen M, Miladinovic V, Hutschemaekers SAJ, Jacobs J, van der Vos C, Wolf AL, Hoogeman MS, van Vulpen M, Bloem JL, P D S Dijkstra S, Peul WC, Penninkhof JJ, Krol ADG.
PMID: 34843840
Radiother Oncol. 2021 Nov 26;166:58-64. doi: 10.1016/j.radonc.2021.11.020. Epub 2021 Nov 26.

BACKGROUND: Due to its specific physical characteristics, proton irradiation is especially suited for irradiation of chordomas and chondrosarcoma in the axial skeleton. Robust plan optimization renders the proton beam therapy more predictable upon individual setup errors. Reported experience with...

Cite
Kroesen M, Miladinovic V, Hutschemaekers SAJ, et al. Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation. Radiother Oncol. 2021;166:58-64doi: 10.1016/j.radonc.2021.11.020.
Kroesen, M., Miladinovic, V., Hutschemaekers, S. A. J., Jacobs, J., van der Vos, C., Wolf, A. L., Hoogeman, M. S., van Vulpen, M., Bloem, J. L., P D S Dijkstra, S., Peul, W. C., Penninkhof, J. J., & Krol, A. D. G. (2021). Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16658-64. https://doi.org/10.1016/j.radonc.2021.11.020
Kroesen, Michiel, et al. "Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 58-64. doi: https://doi.org/10.1016/j.radonc.2021.11.020
Kroesen M, Miladinovic V, Hutschemaekers SAJ, Jacobs J, van der Vos C, Wolf AL, Hoogeman MS, van Vulpen M, Bloem JL, P D S Dijkstra S, Peul WC, Penninkhof JJ, Krol ADG. Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation. Radiother Oncol. 2021 Nov 26;166:58-64. doi: 10.1016/j.radonc.2021.11.020. Epub 2021 Nov 26. PMID: 34843840.
Copy Download .nbib Format: NLM
Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020.

medRxiv : the preprint server for health sciences

Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, Reichmuth ML, Bowen JE, Walls AC, Corti D, Bloom JD, Veesler D, Mateo D, Hernando A, Comas I, González Candelas F, Stadler T, Neher RA.
PMID: 33269368
medRxiv. 2021 Mar 24; doi: 10.1101/2020.10.25.20219063.

Following its emergence in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic resulting in unprecedented efforts to reduce transmission and develop therapies and vaccines (WHO Emergency Committee, 2020; Zhu et al., 2020). Rapidly...

Cite
Hodcroft EB, Zuber M, Nadeau S, et al. Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. medRxiv. 2021;doi: 10.1101/2020.10.25.20219063.
Hodcroft, E. B., Zuber, M., Nadeau, S., Vaughan, T. G., Crawford, K. H. D., Althaus, C. L., Reichmuth, M. L., Bowen, J. E., Walls, A. C., Corti, D., Bloom, J. D., Veesler, D., Mateo, D., Hernando, A., Comas, I., González Candelas, F., Stadler, T., & Neher, R. A. (2021). Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.10.25.20219063
Hodcroft, Emma B, et al. "Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2020.10.25.20219063
Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, Reichmuth ML, Bowen JE, Walls AC, Corti D, Bloom JD, Veesler D, Mateo D, Hernando A, Comas I, González Candelas F, Stadler T, Neher RA. Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. medRxiv. 2021 Mar 24; doi: 10.1101/2020.10.25.20219063. PMID: 33269368; PMCID: PMC7709189.
Copy Download .nbib Format: NLM
Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's Disease Using a Wrist-Worn Accelerometer.

Sensors (Basel, Switzerland)

Habets JGV, Herff C, Kubben PL, Kuijf ML, Temel Y, Evers LJW, Bloem BR, Starr PA, Gilron R, Little S.
PMID: 34883886
Sensors (Basel). 2021 Nov 26;21(23). doi: 10.3390/s21237876.

Motor fluctuations in Parkinson's disease are characterized by unpredictability in the timing and duration of dopaminergic therapeutic benefits on symptoms, including bradykinesia and rigidity. These fluctuations significantly impair the quality of life of many Parkinson's patients. However, current clinical...

Cite
Habets JGV, Herff C, Kubben PL, et al. Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's Disease Using a Wrist-Worn Accelerometer. Sensors (Basel). 2021;21(23)doi: 10.3390/s21237876.
Habets, J. G. V., Herff, C., Kubben, P. L., Kuijf, M. L., Temel, Y., Evers, L. J. W., Bloem, B. R., Starr, P. A., Gilron, R., & Little, S. (2021). Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's Disease Using a Wrist-Worn Accelerometer. Sensors (Basel, Switzerland), 21(23), . https://doi.org/10.3390/s21237876
Habets, Jeroen G V, et al. "Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's Disease Using a Wrist-Worn Accelerometer." Sensors (Basel, Switzerland) vol. 21,23 (2021). doi: https://doi.org/10.3390/s21237876
Habets JGV, Herff C, Kubben PL, Kuijf ML, Temel Y, Evers LJW, Bloem BR, Starr PA, Gilron R, Little S. Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's Disease Using a Wrist-Worn Accelerometer. Sensors (Basel). 2021 Nov 26;21(23). doi: 10.3390/s21237876. PMID: 34883886.
Copy Download .nbib Format: NLM
Communication strategies during the COVID-19 pandemic: Unforeseen opportunities and drawbacks.

Seminars in oncology

Bloom JR, Martin EJ, Jones JA.
PMID: 34736774
Semin Oncol. 2021 Oct 09; doi: 10.1053/j.seminoncol.2021.10.001. Epub 2021 Oct 09.

The current coronavirus pandemic has forced a dramatic shift in the way clinicians practice medicine, including the way we communicate with our patients. The pandemic has both facilitated and challenged serious illness conversations between providers and patients. Furthermore, telemedicine...

Cite
Bloom JR, Martin EJ, Jones JA. Communication strategies during the COVID-19 pandemic: Unforeseen opportunities and drawbacks. Semin Oncol. 2021;doi: 10.1053/j.seminoncol.2021.10.001.
Bloom, J. R., Martin, E. J., & Jones, J. A. (2021). Communication strategies during the COVID-19 pandemic: Unforeseen opportunities and drawbacks. Seminars in oncology, . https://doi.org/10.1053/j.seminoncol.2021.10.001
Bloom, Julie R, et al. "Communication strategies during the COVID-19 pandemic: Unforeseen opportunities and drawbacks." Seminars in oncology vol. (2021). doi: https://doi.org/10.1053/j.seminoncol.2021.10.001
Bloom JR, Martin EJ, Jones JA. Communication strategies during the COVID-19 pandemic: Unforeseen opportunities and drawbacks. Semin Oncol. 2021 Oct 09; doi: 10.1053/j.seminoncol.2021.10.001. Epub 2021 Oct 09. PMID: 34736774; PMCID: PMC8501229.
Copy Download .nbib Format: NLM
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase.

NPJ Parkinson's disease

van Rumund A, Pavelka L, Esselink RAJ, Geurtz BPM, Wevers RA, Mollenhauer B, Krüger R, Bloem BR, Verbeek MM.
PMID: 33741988
NPJ Parkinsons Dis. 2021 Mar 19;7(1):29. doi: 10.1038/s41531-021-00172-z.

Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed in many patients with...

Cite
van Rumund A, Pavelka L, Esselink RAJ, et al. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinsons Dis. 2021;7(1):29doi: 10.1038/s41531-021-00172-z.
van Rumund, A., Pavelka, L., Esselink, R. A. J., Geurtz, B. P. M., Wevers, R. A., Mollenhauer, B., Krüger, R., Bloem, B. R., & Verbeek, M. M. (2021). Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinson's disease, 7(1), 29. https://doi.org/10.1038/s41531-021-00172-z
van Rumund, Anouke, et al. "Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase." NPJ Parkinson's disease vol. 7,1 (2021): 29. doi: https://doi.org/10.1038/s41531-021-00172-z
van Rumund A, Pavelka L, Esselink RAJ, Geurtz BPM, Wevers RA, Mollenhauer B, Krüger R, Bloem BR, Verbeek MM. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. NPJ Parkinsons Dis. 2021 Mar 19;7(1):29. doi: 10.1038/s41531-021-00172-z. PMID: 33741988; PMCID: PMC7979935.
Copy Download .nbib Format: NLM
Showing 289 to 298 of 298 entries